These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22107790)

  • 1. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.
    Cysique LA; Waters EK; Brew BJ
    BMC Neurol; 2011 Nov; 11():148. PubMed ID: 22107790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.
    Calcagno A; Simiele M; Alberione MC; Bracchi M; Marinaro L; Ecclesia S; Di Perri G; D'Avolio A; Bonora S
    Clin Infect Dis; 2015 Jan; 60(2):311-7. PubMed ID: 25281609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease.
    Arendt G; Nolting T; Frisch C; Husstedt IW; Gregor N; Koutsilieri E; Maschke M; Angerer A; Obermann M; Neuen-Jacob E; Adams O; Loeffert S; Riederer P; ter Meulen V; Sopper S;
    J Neurovirol; 2007 Jun; 13(3):225-32. PubMed ID: 17613712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-associated neurological disorders: a guide to pharmacotherapy.
    Tan IL; McArthur JC
    CNS Drugs; 2012 Feb; 26(2):123-34. PubMed ID: 22201342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of cerebrospinal fluid/plasma HIV-RNA discordance with neurocognitive impairment.
    Cárdenas G; López-González M; Monzón-Falconi JF; Soto-Hernández JL; Perales-Martínez D; López-Vejar C
    Natl Med J India; 2015; 28(5):228-32. PubMed ID: 27132951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.
    Strain MC; Letendre S; Pillai SK; Russell T; Ignacio CC; Günthard HF; Good B; Smith DM; Wolinsky SM; Furtado M; Marquie-Beck J; Durelle J; Grant I; Richman DD; Marcotte T; McCutchan JA; Ellis RJ; Wong JK
    J Virol; 2005 Feb; 79(3):1772-88. PubMed ID: 15650202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF penetration by antiretroviral drugs.
    Eisfeld C; Reichelt D; Evers S; Husstedt I
    CNS Drugs; 2013 Jan; 27(1):31-55. PubMed ID: 23160938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV encephalitis in a patient on antiretroviral therapy: a case report.
    Hlebowicz M; Parczewski M; Jakubowski P
    Int J STD AIDS; 2019 May; 30(6):617-619. PubMed ID: 30722753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].
    Sáez-Llorens X; Castrejón de Wong MC; Castaño E; de Suman O; Báez de Ulloa C; Redondo W; Espino M
    Rev Med Panama; 2001; 26():13-8. PubMed ID: 16161718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
    Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
    J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Wright EJ
    Curr Opin HIV AIDS; 2009 Sep; 4(5):447-52. PubMed ID: 20048710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the efficacy of highly active antiretroviral therapy in the brain.
    Kandanearatchi A; Williams B; Everall IP
    Brain Pathol; 2003 Jan; 13(1):104-10. PubMed ID: 12580550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.
    Andersson LM; Hagberg L; Rosengren L; Fuchs D; Blennow K; Gisslén M
    BMC Infect Dis; 2006 Sep; 6():141. PubMed ID: 16978408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
    Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.
    Christo PP; Greco DB; Aleixo AW; Livramento JA
    BMC Infect Dis; 2007 Dec; 7():147. PubMed ID: 18096083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.
    Calcagno A; Barco A; Trunfio M; Bonora S
    Curr HIV/AIDS Rep; 2018 Feb; 15(1):84-91. PubMed ID: 29363025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.